Brain natriuretic peptide (nesiritide) in the treatment of Heart Failure

Cardiovascular Drug Reviews

Volumn 20, Issue 1, 2002, Pages 27-36

  Bettencourt, Paulo ^a,b  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

BNP; Brain natriuretic factor; Heart failure; Nesiritide; Therapy of heart failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NESIRITIDE; NEUROHORMONE;

ADRENERGIC SYSTEM; DIURESIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART RIGHT ATRIUM PRESSURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LUNG WEDGE PRESSURE; NATRIURESIS; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TACHYPHYLAXIS; TREATMENT PLANNING; VASCULAR RESISTANCE; VASODILATATION;

EID: 0036083042     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2002.tb00080.x     Document Type: Review

References (60)

1. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
2. Physiology and therapeutic implications of natriuretic peptides in heart failure
3. Systemic hemodynamic and renal excretory effects of a continuos 4-hour infusion of human brain natriuretic peptide in patients with heart failure
4. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure
5. Clearence function of type C receptors of atrial natriuretic factor in rats
6. Effects of natriuretic peptides as vascular smoth-muscle cells derived from different vascular beds
7. Evaluation of brain natriuretic peptide in the diagnosis of heart failure
8. Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction
9. Predictors of prognosis in patients with stable mild to moderate heart failure
10. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy
11. The natriuretic peptides in heart failure: Diagnosis and therapeutics potentials
12. Detection of left ventricular dysfunction after acute myocardial infarction: Comparison of clinical echographic and neurohormonal methods
13. Brain natriuretic peptide: Effects on left ventricular filling pattern in healthy subjects
14. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure
15. Repetitive bolus administration of brain natriuretic peptide reduces cardiac filling pressures in human heart failure
16. Atrial natriuretic factor in normal subjects and heart failure patients: Plasma levels and renal, hormonal, and hemodynamic response to peptide infusions
17. Intravenous nesiritide, a nathriuretic peptide, in the treatment of decompensated congestive heart failure
18. Value of natriuretic peptides in the assessment of patients with possible new heart failure in primary care
19. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting
20. Plasma brain natriuretic peptide in assessment of acute dyspnoea
21. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats
22. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
23. Renal, endocrine, and hemodynamic effects of human brain natriuretic ppetide in normal man
24. Increased plasma levels and blunted effects of brain natriuretic peptide in rats with congestive heart failure
25. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis
26. Natriuretic peptides
27. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptors ligands by endopeptidase 24.11
28. Mechanism of a trial and brain natriuretic peptide release from rat ventricular myocardium: Effects of stretching
29. Inhibition by atrial and brain natriuretic peptide of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells
30. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long term survival after acute myocardial infarction
31. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction
32. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: A double-blind, placebo-controlled, randomized crossover trial
33. Biochemical detection of left ventricular systolic function
34. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population
35. Brain natriuretic peptide administrated to man: Actions and metabolism
36. Hemodynamic effects of a single intravenous injection of human brain natriuretic peptide (Natrecor) in patients with heart failure
37. Sustained hemodynamic effects of an infusion of nesiritide (human B type natriuretic peptide) in heart failure: A randomized double-blind, placebo controlled clinical trial
38. Plasma BNP as an indicator for angiotensin-converting enzyme inhibition after acute myocardial infarction
39. Increased human brain natriuretic peptide in congestive heart failure
40. Validity of clinical diagnosis of heart failure in primary health care
41. Plasma N-terminal pro-brain natriuretic peptide and adromedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
42. Atrial natriuretic peptide: Synthesis, release, and metabolism
43. A new member of the natriuretic peptide family is present in the venom of the green manba (Dendroaspia angusticepts)
44. A natriuretic peptide in porcine brain
45. C-type natriuretic peptide: A new member of natriuretic peptide family identified in porcine brain
46. Natriuretic peptides in congestive heart failure more than just markers
47. Plasma brain natriuretic peptide levels as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1
48. Attenuation of compensation of endogenous cardiac natruretic system in chronic heart failure. Prognosis role of brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
49. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology
50. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic function and ventricular hypertrophy
51. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failling heart
52. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
53. Increased plasma levels of brain natriuretic peptide in hypertrophic cardiomyopathy
54. Hemodynamic, renal, and hormonal response to brain natriuretic peptide infusion in patients with congestive heart failure
55. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with heart failure
56. Demographic characteristics of patients on the VMAC trial (Vasodilatation in the management of acute congestive heart failure)
57. Vasodilatation in the management of acute congestive heart failure
58. Brain natriuretic peptide in an elderly population
59. Brain natriuretic peptide predicts mortality in the elderly
60. Natriuretic peptide system in human heart failure